Transoral robotic surgery (TORS) in South Africa by Fagan, J J et al.
CORRESPONDENCE
6       January 2017, Vol. 107, No. 1
Transoral robotic surgery (TORS) in 
South Africa 
To the Editor: A series of two-page advertisements have appeared 
in the September and November 2016 issues of the SAMJ, entitled 
‘da Vinci Transoral Robotic Surgery (TORS) is a minimally invasive 
alternative to open surgery and full-dose chemoradiation therapy for 
diseases of the head and neck’. As these advertisements go beyond 
simply marketing surgical equipment, but seek to influence patients, 
referring doctors, oncologists and head and neck surgeons on how to 
treat cancers of the head and neck and sleep apnoea, we have taken 
the unusual step of writing to the editor of the SAMJ to correct some 
misconceptions in the advertisement. 
The objectives of surgical resection of any cancer are to obtain 
clear surgical margins with acceptable morbidity. In the oropha-
rynx, hypopharynx and  larynx this can be achieved  by transoral 
approaches, using either a headlight with electrocautery (as with 
a conventional tonsillectomy) or CO2 laser microsurgery, open 
surgical approaches, or TORS. TORS is simply a surgical tool that 
provides an excellent endoscopic view of the base of tongue, and has 
angled instruments to grab tissues and cut them with electrocautery. 
It is currently licensed by the US Food and Drug Administration 
(FDA) only to be used for T1 and T2 base-of-tongue cancers and 
may be particularly beneficial for selected, difficult-to-get-to cancers 
of the base of tongue. It has been widely adopted in the USA, but 
not in many other regions of the world owing to its very high cost. 
Purchasing a new TORS system is in the order of USD2 million, the 
annual maintenance costs are ~USD165 000, and the cost per case is 
~USD15 000. Because of the high costs, hospitals have been known 
to encourage surgeons to use TORS to resect cancers, which can be 
more cheaply resected with CO2 laser or even with a headlight and 
cautery, to recover their investment.
However, most T1 and T2 base-of-tongue and oropharyngeal 
cancers can be resected with transoral CO2 laser, which is extremely 
cheap compared with TORS and is a well-established validated tech-
nique, also in South Africa (SA). Therefore, while TORS has benefits 
to resect base-of-tongue cancers in cases where CO2 laser does not 
provide adequate access, such cases are uncommon and the costs 
involved simply cannot be justified in the SA healthcare setting. 
Base-of-tongue cancers that cannot be resected by transoral CO2 
laser can still be resected by suprahyoid or lateral pharyngotomy 
approaches, with minimal morbidity. Transoral CO2 laser resec-
tion has all the benefits of TORS listed in the advertisement, such 
as avoiding mandibulotomy, return to speech and swallowing, less 
blood loss, minimal scarring, and avoidance of tracheotomy.
The comment that TORS can reduce the requirement for 
chemoradiotherapy is to date not supported by results from 
randomised clinical trials. The majority of patients who undergo 
surgery for oropharyngeal cancers – especially that involving the 
base of tongue – will require adjuvant treatment to the postoperative 
tumour bed and/or the neck. If the tumour is excised with positive 
margins or the lymph nodes have extracapsular spread, many 
oncologists would still advocate chemoradiation. In theory, if 
a tumour of the base of tongue is excised, the postoperative 
radiotherapy target area may be smaller than if the tumour had not 
been excised. This in turn could result in at least some sparing of the 
pharyngeal constrictor muscles. However, this theoretical advantage 
would not be limited to TORS, but would apply to all the surgical 
techniques mentioned above. 
Several randomised controlled trials are currently underway to 
better define the impact of TORS on the treatment of oropharyngeal 
cancers. In one such study the option of de-escalated treatment after 
TORS is being examined in patients with human papillomavirus 
(HPV)-positive tumours, while another study is comparing TORS 
with/without adjuvant treatment to chemoradiation in patients with 
HPV-negative tumours. Until the results of these and other studies 
are available, the role that TORS (or any surgery that achieves clear 
surgical margins) may or may not play in reducing the need for 
chemoradiotherapy is not known.
Therefore, even though TORS is an established surgical technique, 
it is extremely expensive in the SA context when there are cheaper 
alternatives available.
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